<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01612988</url>
  </required_header>
  <id_info>
    <org_study_id>ICLL01 BOMP</org_study_id>
    <nct_id>NCT01612988</nct_id>
  </id_info>
  <brief_title>Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL</brief_title>
  <acronym>BOMP</acronym>
  <official_title>Phase II Salvage Treatment With Bendamustine, Ofatumumab and MethylPrednisolone (BOMP) in Relapsed B-cell Chronic Lymphocytic Leukemia (B-CLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      ICLL01 The BOMP trial: Phase II study of salvage treatment with Bendamustine, Ofatumumab and&#xD;
      MethylPrednisolone (BOMP) in relapsed B-cell chronic lymphocytic leukemia (B-CLL).&#xD;
&#xD;
      A study of the GOELAMS / GCFLLC-MW intergroup&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Available datas suggest that a combination of bendamustine, ofatumumab and high dose steroids&#xD;
      (the BOMP regimen) appears meaningful and likely to induce a high response rate in patients&#xD;
      with relapsed CLL, including those who have relapsed after modern 1st line&#xD;
      immuno-chemotherapy combinations and those who are fludarabine-refractory. The BOMP trial&#xD;
      will address the complete response rate as its main objective. The results of bendamustine&#xD;
      and rituximab CLL2M trial will serve of a comparator for the BOMP trial. Among secondary&#xD;
      objectives, an extensive study of the p53 pathway (deletion 17p, TP53 mutational status and&#xD;
      p53 function) will be performed and its impact on response and survival will be analyzed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Other drugs others studies&#xD;
  </why_stopped>
  <start_date type="Actual">July 2012</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Response rate according to IWCLL 2008 guidelines</measure>
    <time_frame>9 months</time_frame>
    <description>Complete response rate (CR) at 6 cycles of BOMP according to IWCLL 2008 criteria Hallek 2008</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance and safety</measure>
    <time_frame>57 months</time_frame>
    <description>Tolerance and safety of the BOMP regimen according to the CTC criteria</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">74</enrollment>
  <condition>B-cell Chronic Lymphocytic Leukemia (B-CLL)</condition>
  <arm_group>
    <arm_group_label>Chemotherapy BOMP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine, Ofatumumab and Methylprednisolone prephase and a maximum of 6 cycles every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOMP</intervention_name>
    <description>Day-8 OMB prephase:&#xD;
Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8&#xD;
BOMP cycle 1 and 2 :&#xD;
Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15&#xD;
BOMP cycle 3 to 6 :&#xD;
Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3</description>
    <arm_group_label>Chemotherapy BOMP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years and &lt; 80 years&#xD;
&#xD;
          2. Diagnosis of CLL according IWCLL 2008 criteria and fulfilling a Matutes- Moreau score&#xD;
             ≥ 4&#xD;
&#xD;
          3. Relapsed or refractory CLL stage A, B or C with active disease requiring therapy&#xD;
             according to IWCLL 2008 criteria&#xD;
&#xD;
          4. Relapse or refractory after 1 to 3 previous lines including at least one line with&#xD;
             fludarabine&#xD;
&#xD;
          5. ECOG Performance status and general condition.&#xD;
&#xD;
               -  ECOG Performance status ≤ 2&#xD;
&#xD;
               -  Fit Patients : CIRS (Cumulative Illness Rating Scale) less or equal 6&#xD;
&#xD;
               -  Life expectancy of more than 3 months&#xD;
&#xD;
        Note : Patients fulfilling the above inclusion criteria and presenting with the following&#xD;
        features can also be included:&#xD;
&#xD;
          -  patients with any rate of 17p deletion by FISH&#xD;
&#xD;
          -  patients candidate for an allogeneic transplantation, provided these patients will be&#xD;
             planned to receive the full BOMP treatment program and will have the final restaging&#xD;
             assessment&#xD;
&#xD;
          -  patients with fludarabine refractory disease&#xD;
&#xD;
          -  patients with a prior diagnostic of CLL, at time of previous line(s) of treatment but&#xD;
             who relapse without hyperlymphocytosis (lymphocytes &lt; 5000/mm3) (lymphocytic lymphoma)&#xD;
&#xD;
          -  prior monoclonal antibody (alemtuzumab or rituximab) exposure provided a washout&#xD;
             period of 3 months before the start of the BOMP treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Untreated CLL&#xD;
&#xD;
          2. ECOG Performance Status &gt; 2&#xD;
&#xD;
          3. Serious accompanying disorder or impaired organ function as indicated by:&#xD;
&#xD;
               -  Abnormal renal function with creatinine clearance &lt; 40 ml/min calculated&#xD;
                  according to the formula of Cockcroft and Gault&#xD;
&#xD;
               -  Absolute neutrophils &lt;1,000/mm3, platelets &lt; 75000/mm3 (unless due to malignant B&#xD;
                  Cell involvement of the bone marrow and/or spleen enlargement)&#xD;
&#xD;
               -  Liver tests : total bilirubin &gt;1.5 times UNL (unless due to CLL involvement of&#xD;
                  liver or a known history of Gilbert's disease), transaminases (ALAT, ASAT) and/or&#xD;
                  alkaline phosphatases &gt;2.5 times UNL (unless due to CLL involvement of liver)&#xD;
&#xD;
               -  Clinically significant cardiac disease including unstable angina, acute&#xD;
                  myocardial infarction within six months prior to study enrollment, congestive&#xD;
                  heart failure (NYHA III-IV), and arrhythmia unless controlled by therapy, with&#xD;
                  the exception of extra systoles or minor conduction abnormalities.&#xD;
&#xD;
               -  Severe chronic obstructive pulmonary disease with hypoxemia or pulmonary&#xD;
                  diffusion capacity &lt; 40 %&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus,&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  History of significant cerebrovascular disease in the past 6 months or ongoing&#xD;
                  event with active symptoms or sequelae&#xD;
&#xD;
               -  Significant concurrent, uncontrolled medical condition including, but not limited&#xD;
                  to, renal, hepatic, gastrointestinal, endocrine, pulmonary, neurological,&#xD;
                  cerebral or psychiatric disease which in the opinion of the investigator may&#xD;
                  represent a risk for the patient.&#xD;
&#xD;
          4. CIRS (Cumulative Illness Rating Scale) &gt; 6&#xD;
&#xD;
          5. Clinically significant auto-immune anemia [i.e. any drop in hemogolobin level related&#xD;
             to an hemolytic autoimmune process attested by the following markers : elevated&#xD;
             indirect bilirubin, elevated LDH, low haptoglobin levels, high reticulocytes count&#xD;
             along with a positive direct anti-erythrocyte test (Coombs direct test)]&#xD;
&#xD;
          6. Transformation to an aggressive B-cell malignancy (e.g. diffuse large cell lymphoma,&#xD;
             Hodgkin's lymphoma, or prolymphocytic leukaemia)&#xD;
&#xD;
          7. Prior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 3 months&#xD;
             prior to start of therapy.&#xD;
&#xD;
          8. Prior autologous transplantation or allogeneic transplantation&#xD;
&#xD;
          9. Prior treatment with bendamustine and/or ofatumumab&#xD;
&#xD;
         10. Active second malignancy currently requiring treatment (except basal cell carcinoma,&#xD;
             in situ cervix carcinoma and incidental prostate carcinoma). Subjects who have been&#xD;
             free of malignancy for at least 5 years are eligible.&#xD;
&#xD;
         11. Known HIV-positivity&#xD;
&#xD;
         12. Positive serology for hepatitis B (HB) (except post vaccinale pattern) and/or for&#xD;
             hepatitis C. Positive serology for HB is defined as a positive test for HBs antigen or&#xD;
             for anti-HBc antibodies (regardless of HBsAb status).&#xD;
&#xD;
         13. Current active hepatic or biliary disease (with exception of patients with Gilbert's&#xD;
             syndrome, asymptomatic gallstones, or stable chronic liver disease per investigator&#xD;
             assessment)&#xD;
&#xD;
         14. Simultaneous participation in another study protocol&#xD;
&#xD;
         15. Known hypersensitivity to the medications to be used specially to humanized monoclonal&#xD;
             antibodies or any of the study drugs&#xD;
&#xD;
         16. Chronic or current bacterial, viral or fungal infectious disease requiring systemic&#xD;
             antibiotics, antifungal, or antiviral treatment such as, but not limited to, chronic&#xD;
             renal infection, chronic chest infection with bronchiectasis, tuberculosis&#xD;
&#xD;
         17. Any coexisting medical or psychological condition that would preclude participation in&#xD;
             the required study procedures&#xD;
&#xD;
         18. Patient with mental deficiency preventing proper understanding of the requirements of&#xD;
             treatment.&#xD;
&#xD;
         19. Pregnant or breastfeeding women.&#xD;
&#xD;
         20. Person major under law-control&#xD;
&#xD;
         21. Lactating women&#xD;
&#xD;
         22. Fertile male and female patients who cannot or do not wish to use an effective method&#xD;
             of contraception, during and for 12 months after the final treatment used for the&#xD;
             purposes of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier TOURNILHAC, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sophie DE GUIBERT, MD PD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tournilhac</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO Internet site</description>
  </link>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2012</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B-cell chronic lymphocytic leukemia</keyword>
  <keyword>relapse</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>Ofatumumab</keyword>
  <keyword>Méthylprednisolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

